| Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. | |
| | |
MedLine Citation:
|
PMID: 12563267 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Atrophy of skeletal muscle is a serious consequence of numerous diseases, including cancer and AIDS. Successful treatments for skeletal muscle atrophy could either block protein degradation pathways activated during atrophy or stimulate protein synthesis pathways induced during skeletal muscle hypertrophy. This perspective will focus on the signalling pathways that control skeletal muscle atrophy and hypertrophy, including the recently identified ubiquitin ligases muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx), as a basis to develop targets for pharmacologic intervention in muscle disease. |
| | |
Authors:
|
David J Glass |
Related Documents
:
|
3098997 - Effects of resistive exercise on skeletal muscle in marrow transplant recipients receiv... 9815007 - Testosterone injection stimulates net protein synthesis but not tissue amino acid trans... 6809327 - Metabolism in peripheral tissues in cancer patients. 20568147 - Aerosol formation during the microwave freeze dehydration of beef. 19062307 - The activity pattern of shoulder muscles in subjects with and without subacromial impin... 7820977 - Growth hormone (gh) treatment in gh-deficient adults: effects on muscle size, strength ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Nature cell biology Volume: 5 ISSN: 1465-7392 ISO Abbreviation: Nat. Cell Biol. Publication Date: 2003 Feb |
Date Detail:
|
Created Date: 2003-02-03 Completed Date: 2003-03-27 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 100890575 Medline TA: Nat Cell Biol Country: England |
Other Details:
|
Languages: eng Pagination: 87-90 Citation Subset: IM |
Affiliation:
|
Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, USA. david.glass@regeneron.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
1-Phosphatidylinositol 3-Kinase
/
metabolism Animals Calcineurin / metabolism Humans Hypertrophy / metabolism Insulin-Like Growth Factor I / metabolism Ligases / metabolism Muscle Proteins / metabolism Muscle, Skeletal / metabolism*, pathology* Muscular Atrophy / metabolism* Protein-Serine-Threonine Kinases* Proto-Oncogene Proteins / metabolism Proto-Oncogene Proteins c-akt Receptors, Adrenergic, beta-2 / metabolism SKP Cullin F-Box Protein Ligases* Signal Transduction / physiology* Ubiquitin-Protein Ligases* |
| Chemical | |
Reg. No./Substance:
|
0/Muscle Proteins; 0/Proto-Oncogene Proteins; 0/Receptors, Adrenergic, beta-2; 67763-96-6/Insulin-Like Growth Factor I; EC 2.7.1.137/1-Phosphatidylinositol 3-Kinase; EC 2.7.11.1/Protein-Serine-Threonine Kinases; EC 2.7.11.1/Proto-Oncogene Proteins c-akt; EC 3.1.3.16/Calcineurin; EC 6.-/Ligases; EC 6.3.2.19/FBXO32 protein, human; EC 6.3.2.19/SKP Cullin F-Box Protein Ligases; EC 6.3.2.19/TRIM63 protein, human; EC 6.3.2.19/Ubiquitin-Protein Ligases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Combinations of muscle synergies in the construction of a natural motor behavior.
Next Document: Developmental control of cell morphogenesis: a focus on membrane growth.